Suppression of the biological activity of neuroglioma cells by down-regulation of miR-1.
, “Suppression of the biological activity of neuroglioma cells by down-regulation of miR-1.”, Genet Mol Res, vol. 16, no. 3, 2017.
Glioma
Association of three common single nucleotide polymorphisms of SLC7A7 with the development of glioma in a Chinese population.
, “Association of three common single nucleotide polymorphisms of SLC7A7 with the development of glioma in a Chinese population.”, Genet Mol Res, vol. 16, no. 2, 2017.
Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells.
, “Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells.”, Genet Mol Res, vol. 16, no. 1, 2017.
Mechanism of SEMA3B gene silencing and clinical significance in glioma
, “Mechanism of SEMA3B gene silencing and clinical significance in glioma”, vol. 15, p. -, 2016.
The aim of the current study was to explore mechanisms of SEMA3B gene expression and its clinical significance in glioma, and provide a theoretical foundation for investigating individualized treatment in glioma. Paraffin-embedded tissues from 43 patients with a confirmed clinical diagnosis of glioma following neurosurgery at the First Affiliated Hospital of Zhengzhou University from December 2013 to April 2014 were selected randomly.
CCDC26 rs4295627 polymorphism (8q24.21) and glioma risk: a meta-analysis
, “CCDC26 rs4295627 polymorphism (8q24.21) and glioma risk: a meta-analysis”, vol. 14, pp. 12074-12084, 2015.
The association between the CCDC26 rs4295627 single nucleotide polymorphism (SNP) and the glioma risk has been studied previously, but these studies have yielded conflicting results. The aim of the present study is to analyze this association more vigorously, by means of a meta-analysis. A comprehensive literature search was performed in databases PubMed and EMBASE. Six articles including 12 case-control studies in English with 11,368 controls and 5891 cases were eligible for the meta-analysis.
Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis
, “Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis”, vol. 14, pp. 12577-12584, 2015.
Several studies have focused on the association between the ERCC2 rs13181 polymorphism and glioma risk, but the results were inconclusive. We aimed to conduct a meta-analysis to investigate the role of ERCC2 rs13181 on the risk of glioma. We searched and collated the relevant studies in both Chinese and English through the PubMed, Web of Science, Cochrane Library, and EMBASE databases published through June 1, 2014. A total of 11 studies for ERCC2 rs13181 were selected; these included 3456 glioma cases and 4957 controls.
CXCL12 G801A polymorphism and susceptibility to glioma: a case‑control study
, “CXCL12 G801A polymorphism and susceptibility to glioma: a case‑control study”, vol. 14, pp. 17399-17405, 2015.
Previous studies have demonstrated that the CXCL12 G801A polymorphism is closely correlated with tumor susceptibility. In addition, the CXCL12/CXCR4 pathway is closely related to proliferation, metastasis, and invasion of glioma. However, the genetic effects of the CXCL12 G801A polymorphism on glioma risk in Chinese populations remain unknown. In this study, we investigated the potential associations between the CXCL12 G801A polymorphism with glioma susceptibility and its clinicopathological characteristics.
Differentiation-inducing effects of betamethasone on human glioma cell line U251
, “Differentiation-inducing effects of betamethasone on human glioma cell line U251”, vol. 14, pp. 7841-7849, 2015.
We studied the differentiation-inducing effect of betamethasone on human glioma cell line U251 cultured in vitro, and the underlying mechanism. U251 cells were divided into two groups: control group cells, cultured in Dulbecco’s Modified Eagle’s medium containing 10% fetal bovine serum; and medication group cells, treated with 15 μM betamethasone. Morphological cell changes were observed by inverted microscope, cell cycle changes were ascertained by flow cytometry, and vimentin expression was checked by immunocytochemistry.
DNA repair gene XRCC3 variants are associated with susceptibility to glioma in a Chinese population
, “DNA repair gene XRCC3 variants are associated with susceptibility to glioma in a Chinese population”, vol. 14, pp. 10569-10575, 2015.
The susceptibility to glioma is not well understood. It has been suggested that the X-ray cross complementing group 3 (XRCC3) gene influences the capacity to repair DNA damage, leading to increased glioma susceptibility. In this study, we evaluated the relationship between XRCC3 mutations and glioma risk. Genotypes were assessed in 389 Chinese glioma patients and 358 healthy controls. XRCC3 Thr241Met (rs861539) and 2 additional polymorphisms, rs3212112 (c.774+19T>G) and rs1799796 (c.562-14A>G), were directly sequenced.
